Filing Details

Accession Number:
0001209191-19-031213
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-05-20 07:18:18
Reporting Period:
2019-05-16
Accepted Time:
2019-05-20 07:18:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
818686 Teva Pharmaceutical Industries Ltd TEVA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1719114 Carlo Notaristefani De C/O Teva Pharmaceutical Industries Ltd.
5 Basel Street
Petach Tikva L3 4951033
Executive Vp Global Operations No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2019-05-16 1,204 $0.00 19,413 No 4 M Direct
Ordinary Shares Disposition 2019-05-16 629 $11.76 18,784 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Restricted Share Units Disposition 2019-05-16 1,204 $0.00 1,204 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 M Direct
Footnotes
  1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  2. The Ordinary Shares were received for no consideration upon the satisfaction of performance criteria underlying an award of performance share units.
  3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  4. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
  5. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  6. Restricted share units were granted on February 12, 2019 pursuant to the satisfaction of performance criteria and vested on May 16, 2019.